HIES Clinical Trials in Houston, Texas
8 recruitingHouston, Texas
Showing 1–8 of 8 trials
Recruiting
Phase 1Phase 2
A Phase 1/2 Study of NKX019 in Subjects With Immune-Mediated Diseases (Ntrust-2)
Idiopathic Inflammatory MyopathiesSystemic SclerosisAntineutrophil Cytoplasmic Antibody-associated Vasculitis
Nkarta, Inc.144 enrolled15 locationsNCT06733935
Recruiting
Phase 2
Study of WAL0921 in Patients With Glomerular Kidney Diseases
Diabetic NephropathiesPrimary Focal Segmental GlomerulosclerosisMinimal Change Disease+2 more
Walden Biosciences96 enrolled50 locationsNCT06466135
Recruiting
Phase 4
The PIVATAL Study -Study of Ventricular Arrhythmia (VTA) Ablation in Left Ventricular Assist Device (LVAD) Patients
CardiomyopathiesArrythmia
University of Rochester100 enrolled19 locationsNCT05034432
Recruiting
Phase 1Phase 2
A Repeat-Dose, Open-Label, Two Arm Safety and Efficacy Study of Two Doses of VP-001 Administered Intravitreally in Participants With Confirmed PRPF31 Mutation-Associated Retinal Dystrophy, Including Participants Previously Treated With VP001
Retinal DegenerationRetinal DiseaseRetinal Dystrophies+2 more
PYC Therapeutics16 enrolled6 locationsNCT06852963
Recruiting
The Myelin Disorders Biorepository Project
AdrenoleukodystrophyCockayne SyndromeRefsum Disease+63 more
Children's Hospital of Philadelphia12,000 enrolled23 locationsNCT03047369
Recruiting
TRANSPIRE: Lung Injury in a Longitudinal Cohort of Pediatric HSCT Patients
Hematopoietic Stem Cell Transplant (HSCT)Thrombotic MicroangiopathiesDiffuse Alveolar Hemorrhage+2 more
Children's Hospital Medical Center, Cincinnati2,000 enrolled9 locationsNCT04098445
Recruiting
Phase 2
Efficacy and Safety Study of Narsoplimab in Pediatric Patients With High-Risk Hematopoietic Stem Cell Transplant TMA
Hematopoietic Stem Cell TransplantationThrombotic Microangiopathies
Omeros Corporation18 enrolled16 locationsNCT05855083
Recruiting
Phase 1
MAD of IVT VP-001 in PRPF31 Mutation-Associated Retinal Dystrophy Subjects (Wallaby)
Retinal DegenerationRetinal DiseaseEye Diseases+2 more
PYC Therapeutics12 enrolled5 locationsNCT06455826